All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract | Phase III trial of gilteritinib maintenance therapy in patients with mutated FLT3-ITD AML (MORPHO)
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the key results from the phase III randomized placebo-controlled MORPHO trial (NCT02997202) evaluating gilteritinib as a maintenance therapy in patients with FLT3-internal tandem duplication (ITD) acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation in first remission.1
Results from the MORPHO trial were presented by Levis1 at the European Hematology Association (EHA) 2023 Hybrid Congress. The findings of this study suggest that post-allo-HSCT gilteritinib maintenance therapy could be the standard of care for patients with FLT3-ITD acute myeloid leukemia who are measurable residual disease positive pre- or post-allo-HSCT.
- Levis MJ. BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as posttransplant maintenance for FLT3-ITD AML. Oral abstract #LB2711. European Hematology Association (EHA) 2023 Hybrid Congress; Jun 11, 2023; Frankfurt, DE.
Your opinion matters
28 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox